Suppr超能文献

[用于转移性或复发性结直肠癌的FOLFIRI方案]

[FOLFIRI regimen for metastatic or recurrent colorectal cancer].

作者信息

Uemura Norihisa, Yamada Yasuhide

机构信息

Dept. of Gastrointestinal Oncology, National Cancer Center Hospital.

出版信息

Gan To Kagaku Ryoho. 2006 Jul;33(7):904-6.

Abstract

Irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and Leucovorin (LV) became the standard first-line chemotherapy for colorectal cancer in the U.S. and Europe in 2000, largely owing to the results of controlled randomized phase III trials of 5-FU/LV with or without CPT-11. One of the regimens for CPT-11 plus infusional 5-FU/LV therapy is the FOLFIRI regimen. This regimen consists of CPT-11 180 mg/m(2) as a 90-min infusion on day 1 and l-LV 200 mg/m(2) as a 2-h infusion during CPT-11, immediately followed by a bolus dose of 5-FU 400 mg/m(2) and a 46-h continuous infusion of 2,400 mg/m(2) every 2 weeks. FOLFIRI, as well as oxaliplatin/5-FU/LV therapy (FOLFOX), is an internationally accepted standard chemotherapy for metastatic colorectal cancer. Safe use of this effective regimen requires adequate supportive therapy in Japan, as well as in Western countries.

摘要

2000年,伊立替康(CPT - 11)联合5 - 氟尿嘧啶(5 - FU)和亚叶酸钙(LV)成为美国和欧洲治疗结直肠癌的标准一线化疗方案,这主要归功于含或不含CPT - 11的5 - FU/LV对照随机III期试验结果。CPT - 11联合5 - FU/LV持续静脉滴注疗法的方案之一是FOLFIRI方案。该方案包括第1天静脉滴注90分钟的CPT - 11 180 mg/m²,在CPT - 11静脉滴注期间静脉滴注2小时的l - LV 200 mg/m²,随后立即静脉推注400 mg/m²的5 - FU,并每2周持续静脉滴注46小时2400 mg/m²。FOLFIRI以及奥沙利铂/5 - FU/LV疗法(FOLFOX)是国际上公认的转移性结直肠癌标准化疗方案。在日本以及西方国家,安全使用这种有效方案需要充分的支持治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验